Senior Editor – Europe
Latest From David Ridley
LanesHealth's UK supplement brands Pro Plus and Gopo get on-trend line extenstions in the areas of cognitive health and natural medicinal alternatives.
UK men's health platform Numan continues its mission of disrupting the consumer health industry with its acquisition of Sweden’s Vi-Health technology – a Class I medical device that includes an artificial intelligence-powered symptom checker, as well as advanced e-consultation and workflow automation tools.
The "shakers and movers" in the European cannabidiol market in the next two to three years will be big pharma, says Irish synthetic CBD specialist Chanelle McCoy Health. With its purported health benefits, CBD will also need to go the way of OTC drugs, with medicinal claims supported by clinical trials, the firm predicts.
Australia's Starpharma has launched in the UK its Viraleze antiviral COVID-19 nasal spray. On pack messaging states that the product "inactivates respiratory viruses, including >99.9% of coronavirus SARS-CoV-2."
Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.
HBW editors Tom Gallen and David Ridley discuss the big issues in the European consumer health market from the past week. In this edition, they delve into CBD, probiotics, and GSK's sustainability plans.